Trials / Completed
CompletedNCT01300650
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, non-randomized, pilot-study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with heart failure. Subjects will undergo cardiopulmonary exercise testing at baseline and after 2-weeks treatment with anakinra (recombinant human Interleukin-1 receptor antagonist).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra | Anakinra 100 mg subcutaneous injection daily |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2011-02-21
- Last updated
- 2017-11-30
- Results posted
- 2013-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01300650. Inclusion in this directory is not an endorsement.